Arcus Biosciences (NYSE:RCUS) Releases Earnings Results, Misses Expectations By $0.02 EPS

Arcus Biosciences (NYSE:RCUS) posted its quarterly earnings data on Tuesday. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02), Fidelity Earnings reports. Arcus Biosciences had a negative return on equity of 36.93% and a negative net margin of 1,180.37%. The company had revenue of $1.75 million for the quarter, compared to analysts’ expectations of $1.34 million.

Arcus Biosciences stock traded down $0.07 during midday trading on Friday, hitting $7.53. 4,926 shares of the stock were exchanged, compared to its average volume of 298,614. The company has a fifty day simple moving average of $8.46 and a two-hundred day simple moving average of $8.56. Arcus Biosciences has a 52 week low of $6.30 and a 52 week high of $13.77. The stock has a market capitalization of $383.30 million, a PE ratio of -5.27 and a beta of 0.99.

A number of analysts have recently weighed in on RCUS shares. Zacks Investment Research lowered Arcus Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday. ValuEngine upgraded shares of Arcus Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Mizuho restated a “buy” rating on shares of Arcus Biosciences in a research report on Sunday, October 20th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $16.69.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.

Recommended Story: What is Green Investing?

Earnings History for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with's FREE daily email newsletter.